CN117295755A - Psd-95抑制剂及其用途 - Google Patents

Psd-95抑制剂及其用途 Download PDF

Info

Publication number
CN117295755A
CN117295755A CN202280033562.9A CN202280033562A CN117295755A CN 117295755 A CN117295755 A CN 117295755A CN 202280033562 A CN202280033562 A CN 202280033562A CN 117295755 A CN117295755 A CN 117295755A
Authority
CN
China
Prior art keywords
compound
seq
cpp
peptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280033562.9A
Other languages
English (en)
Chinese (zh)
Inventor
V·塞雷凯特
C·R·O·比奇-巴特林
K·斯特罗姆戈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Københavns Universitet
Original Assignee
Københavns Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Københavns Universitet filed Critical Københavns Universitet
Publication of CN117295755A publication Critical patent/CN117295755A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280033562.9A 2021-05-12 2022-05-12 Psd-95抑制剂及其用途 Pending CN117295755A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173587 2021-05-12
EP21173587.3 2021-05-12
PCT/EP2022/062893 WO2022238530A1 (en) 2021-05-12 2022-05-12 Psd-95 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN117295755A true CN117295755A (zh) 2023-12-26

Family

ID=75914418

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280033562.9A Pending CN117295755A (zh) 2021-05-12 2022-05-12 Psd-95抑制剂及其用途

Country Status (16)

Country Link
US (1) US20240245793A1 (cg-RX-API-DMAC10.html)
EP (1) EP4337673B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024520234A (cg-RX-API-DMAC10.html)
KR (1) KR20240007140A (cg-RX-API-DMAC10.html)
CN (1) CN117295755A (cg-RX-API-DMAC10.html)
AU (1) AU2022274309A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023021410A2 (cg-RX-API-DMAC10.html)
CA (1) CA3218073A1 (cg-RX-API-DMAC10.html)
ES (1) ES3040762T3 (cg-RX-API-DMAC10.html)
IL (1) IL307244A (cg-RX-API-DMAC10.html)
MX (1) MX2023013313A (cg-RX-API-DMAC10.html)
PL (1) PL4337673T3 (cg-RX-API-DMAC10.html)
SA (1) SA523451347B1 (cg-RX-API-DMAC10.html)
TW (1) TW202306965A (cg-RX-API-DMAC10.html)
WO (1) WO2022238530A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202308712B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4706670A1 (en) * 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
WO2025009503A1 (ja) * 2023-07-03 2025-01-09 メスキュージェナシス株式会社 細胞膜透過性を有するペプチドおよびそのスクリーニング方法
WO2025051130A1 (zh) * 2023-09-07 2025-03-13 湖南中晟全肽生物科技股份有限公司 作为神经保护剂的药用化合物及其应用
CN117164725B (zh) * 2023-09-07 2024-05-10 湖南中晟全肽生物科技股份有限公司 一种突触后密度蛋白-95抑制剂多肽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2320927T3 (pl) 2008-07-09 2016-02-29 Univ Copenhagen Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
KR102046830B1 (ko) 2011-05-13 2019-11-20 코벤하븐스 유니버시테트 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제
WO2020083905A1 (en) * 2018-10-22 2020-04-30 University Of Copenhagen Inhibitors of pick1 and uses thereof

Also Published As

Publication number Publication date
KR20240007140A (ko) 2024-01-16
IL307244A (en) 2023-11-01
CA3218073A1 (en) 2022-11-17
US20240245793A1 (en) 2024-07-25
TW202306965A (zh) 2023-02-16
BR112023021410A2 (pt) 2023-12-19
AU2022274309A1 (en) 2023-09-28
MX2023013313A (es) 2023-12-04
EP4337673B1 (en) 2025-07-09
SA523451347B1 (ar) 2024-08-27
AU2022274309A9 (en) 2024-01-25
EP4337673A1 (en) 2024-03-20
ZA202308712B (en) 2025-02-26
WO2022238530A1 (en) 2022-11-17
PL4337673T3 (pl) 2026-01-05
ES3040762T3 (en) 2025-11-04
JP2024520234A (ja) 2024-05-23
EP4337673C0 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
JP6480865B2 (ja) 新規なα４β７ペプチド二量体拮抗薬
ES3040762T3 (en) Psd-95 inhibitors and uses thereof
US6001961A (en) Cyclic adhesion inhibitors
KR102787208B1 (ko) α4β7 인테그린 티오에테르 펩티드 길항제
CN101678213B (zh) 环肽cxcr4拮抗剂
CN103533949B (zh) 作为缺血性脑损伤的有效神经保护剂并用于治疗疼痛的psd-95的高亲和力的二聚抑制剂
KR20160011625A (ko) 새로운 α4β7 펩타이드 이량체 길항제들
JP6633523B2 (ja) Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体
AU2021309548A1 (en) Inhibitors of complement factor C3 and their medical uses
HUP0201925A2 (en) Cyclic peptide derivatives as inhibitors of integrin alphavbeta6 and their use
JP2599947B2 (ja) ペプチド化合物
WO1992007870A1 (en) Platelet aggregation inhibitors
US20170246311A1 (en) Peptides for binding alternatively activated macrophages
CA2937032C (en) Activated neurotensin molecules and the uses thereof
HK40108323B (en) Psd-95 inhibitors and uses thereof
HK40108323A (en) Psd-95 inhibitors and uses thereof
HUP0201729A2 (en) Inhibitors of the integrin alpha v betha 6
US8076453B2 (en) Kinin B1 receptor peptide agonists and uses thereof
HK40112064A (en) Crf2 receptor agonists and their use in therapy
JP2024536413A (ja) 二環式ペプチドリガンド薬物コンジュゲート

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination